📍 Krascendo 1 🫁 #krasg12c #nsclc #esmo2026 #presidentialSymposium2

Phase 3, global, randomised trial of divarasib vs sotorasib or adagrasib in advanced/metastatic KRAS G12C-mutated NSCLC.

🍁Results🍀
-A significant benefit in PFS (HR: 0.58; 95% CI: 0.44–0.76), 9.8 vs 5.7 months for diva vs soto/ ada .
-A significant benefit in OS (HR: 0.56; 95% CI: 0.41–0.78) , 17.7 vs 11 months for diva vs soto/ ada
-A significant improvement in ORR was seen for diva (58.4%) vs soto/ ada (32.3%)

@myESMO @HemOncFellows @IMG_Oncologists @hemeoncfellow